Louisiana State Employees Retirement System Invests $15.22 Million in Merck & Co., Inc. $MRK

Louisiana State Employees Retirement System acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 126,500 shares of the company’s stock, valued at approximately $15,217,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $25,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $31,000. Finally, High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. CICC Research initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday. They set an “outperform” rating and a $138.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. UBS Group upped their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $128.72.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The European Commission approved Keytruda plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer, expanding Merck’s oncology franchise in Europe. European Commission Approves KEYTRUDA Plus Padcev
• Positive Sentiment: The FDA approved Keytruda and Keytruda Qlex, each combined with Gilead’s Trodelvy, as a first-line treatment for PD-L1-positive advanced triple-negative breast cancer, adding another growth opportunity for the drug. FDA Approves Keytruda and Trodelvy for TNBC
• Positive Sentiment: Analyst commentary has also been supportive, with CICC Research initiating coverage at outperform and a price target above the recent trading range, reinforcing bullish sentiment around the stock. Merck Coverage Update
• Neutral Sentiment: Other reports noted that competitor Gilead won EC approval to expand Trodelvy’s label in metastatic TNBC, which is relevant to Merck because Trodelvy is part of the newly approved Keytruda combination, but the net market impact is still unclear. Gilead Wins EC Approval to Expand Trodelvy’s Label
• Neutral Sentiment: Several analyst notes were mixed, including Citi’s hold rating and Scotiabank’s buy rating, suggesting the latest move is being driven more by product news than by a major change in analyst consensus. Citi Keeps Their Hold Rating on Merck & Company

Merck & Co., Inc. Trading Up 3.9%

Shares of MRK stock opened at $125.36 on Friday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The stock has a market capitalization of $309.61 billion, a price-to-earnings ratio of 35.31, a price-to-earnings-growth ratio of 2.71 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.96. The stock’s 50-day moving average price is $115.88 and its 200-day moving average price is $114.23.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.